Peptide Drug Semax Shows Promise Against Alzheimer's Disease in Mouse Model
The neuroprotective peptide Semax and its derivative improved behavior and reduced amyloid pathology in a transgenic Alzheimer's mouse model.
Quick Facts
What This Study Found
Semax and its derivative improved behavioral performance and reduced amyloidosis in transgenic Alzheimer's mice, suggesting neuroprotective potential.
Key Numbers
APPswe/PS1dE9/Blg transgenic mice; improved performance in open field, novel object recognition, and Barnes maze tests; reduced amyloidosis.
How They Did This
Preclinical study in transgenic APPswe/PS1dE9/Blg mice using open field, novel object recognition, and amyloid pathology assessment.
Why This Research Matters
Safe, effective Alzheimer's treatments remain elusive; natural neuroprotective peptides like Semax could offer therapeutic benefits without the significant side effects seen in antibody-based amyloid therapies.
The Bigger Picture
As antibody-based amyloid treatments face safety concerns (brain swelling, microbleeds), peptide-based neuroprotective approaches like Semax represent a potentially safer alternative strategy for Alzheimer's disease.
What This Study Doesn't Tell Us
Mouse model study — results may not translate directly to human Alzheimer's; specific dosing, treatment duration, and long-term effects need further investigation.
Questions This Raises
- ?Can Semax or its derivatives cross the blood-brain barrier efficiently enough for human therapeutic use?
- ?Would Semax work synergistically with existing Alzheimer's treatments?
Trust & Context
- Key Stat:
- Reduced amyloidosis Semax peptide decreased amyloid plaque pathology in Alzheimer's model mice
- Evidence Grade:
- Preclinical animal study; promising results but human clinical trials are needed to confirm efficacy and safety.
- Study Age:
- Published in 2025, contributing to the growing body of peptide-based neurotherapeutic research.
- Original Title:
- The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.
- Published In:
- Acta naturae, 17(4), 110-120 (2025)
- Authors:
- Radchenko, A I, Kuzubova, E V, Apostol, A A, Mitkevich, V A, Andreeva, L A, Limborska, S A, Stepenko, Yu V, Shmigerova, V S, Solin, A V, Korokin, M V, Pokrovskii, M V, Myasoedov, N F, Makarov, A A
- Database ID:
- RPEP-13162
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is Semax?
Semax is a synthetic peptide derived from ACTH (adrenocorticotropic hormone) that has neuroprotective properties. It is used clinically in some countries for cognitive enhancement and stroke recovery, and is now being studied for Alzheimer's disease.
Could peptide drugs treat Alzheimer's disease?
This study suggests peptide drugs like Semax may reduce Alzheimer's-related brain pathology and improve behavior in animal models. Unlike antibody treatments that can cause brain swelling, peptide drugs may offer a safer therapeutic approach, though human trials are still needed.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13162APA
Radchenko, A I; Kuzubova, E V; Apostol, A A; Mitkevich, V A; Andreeva, L A; Limborska, S A; Stepenko, Yu V; Shmigerova, V S; Solin, A V; Korokin, M V; Pokrovskii, M V; Myasoedov, N F; Makarov, A A. (2025). The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.. Acta naturae, 17(4), 110-120. https://doi.org/10.32607/actanaturae.27808
MLA
Radchenko, A I, et al. "The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.." Acta naturae, 2025. https://doi.org/10.32607/actanaturae.27808
RethinkPeptides
RethinkPeptides Research Database. "The Potential of the Peptide Drug Semax and Its Derivative f..." RPEP-13162. Retrieved from https://rethinkpeptides.com/research/radchenko-2025-the-potential-of-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.